Abstracts from USCAP 2020: Pancreas, Gallbladder, Ampulla, and Extra-Hepatic Biliary Tree (1739-1801)

Jason L. Hornick,Rhonda K. Yantiss,Laura W. Lamps,Cme Subcommittee,Steven D. Billings,Raja R. Seethala,Ilan Weinreb,David Kaminsky,Zubair Baloch,Daniel J. Brat,Ashley Cimino‐Mathews,James R. Cook,Sarah Dry,William C. Faquin,Yuri Fedoriw,Karen Fritchie,Lakshmi Priya,Kunju Anna,Marie Mulligan,Rish K. Pai,David Papke,Vinita Parkash,Carlos Parra‐Herran,Anil V. Parwani,Beena U Ahsan,Kannan Thanikachalam,Ariane Robison,Jia Li,Indrani Datta,Ifeoma Onwubiko,Gazala Khan,Mohammad Raoufi,: None,Munita Bal,Aishwarya Sharma,Rajiv Kumar,Kedar Deodhar,Mukta Ramadwar,Serdar Balcı,Michelle D. Reid,İpek Erbarut Seven,Burcu Saka,Burçin Pehlivanoğlu,Bahar Memiş,Pelin Bağcı,Olca Baştürk,N. Volkan Adsay,Philippe Echelard,Yves Collin,Sameh Geha

DOI: https://doi.org/10.1038/s41379-020-0482-7

IF: 8.209

2020-01-01

Modern Pathology

Abstract:Background: Pancreatic neuroendocrine tumors (PNET) have an unpredictable biological behavior that cannot be reliably predicted by histological and clinical manifestations.We performed next generation sequencing (NGS) on PNET to understand the molecular pathogenesis and to identify potential biomarkers correlating with metastases and survival.Design: Hybrid capture-based comprehensive genomic profiling was performed on both primary and metastatic PNET from 28 patients.Metastatic sites were grouped as lymph nodes and distant metastases (consisted of liver followed by bone).NGS was performed on genomic DNA & RNA isolated from formalin-fixed paraffin embedded tissue using the whole exome NGS assay covering 20,000 genes.Average number of DNA reads was 52 million at 3:1 somatic to germline.All variants were detected with >99% confidence based on allele frequency and amplicon coverage, with an average sequencing depth of coverage >500x and an analytical sensitivity of 5%.Tumor mutation burden and MSI status were compared using the two-sample t-test between tumor types.Frequency of mutations in each gene was compared between tumor types using the Fisher's exact test.To account for multiple comparisons, the False Discovery Rate was estimated using Benjamini-Hochberg procedure.R package "maftools" was used to summarize and visualize the findings.Results: Mutation burden was higher in primary tumors with metastases versus primary tumors without metastases (p=0.034) while no significance was found in MSI status between these two groups.